Deferasirox-Mepha
Deferasirox-Mepha is a generic from Mepha Pharma AG and is listed on the FOPH Specialities List. Basic health insurance reimburses it within the authorised indication. The public price ranges from CHF 172.40 to CHF 1'086.05 depending on the pack; the co-payment is 10 per cent.
Core data
- Authorisation holder
- Mepha Pharma AG
- ATC code
- V03AC03
- IT group
- 06.99 Varia
- Active substances
- Deferasiroxum
- Preparation type
- Generic
- On the SL since
- 01/03/2024
- Last price change
- 01/12/2024
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Lactab 90 mg | Blist 30 Stk | CHF 143.41 | CHF 172.40 | 01/03/2024 | B | 7680676780012 |
| Lactab 90 mg | Blist 90 Stk | CHF 365.68 | CHF 414.10 | 01/03/2024 | B | 7680676780029 |
| Lactab 180 mg | Blist 30 Stk | CHF 235.19 | CHF 272.20 | 01/03/2024 | B | 7680676780036 |
| Lactab 180 mg | Blist 90 Stk | CHF 599.72 | CHF 668.65 | 01/03/2024 | B | 7680676780043 |
| Lactab 360 mg | Blist 30 Stk | CHF 385.70 | CHF 435.90 | 01/03/2024 | B | 7680676780050 |
| Lactab 360 mg | Blist 90 Stk | CHF 983.53 | CHF 1'086.05 | 01/03/2024 | B | 7680676780067 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
- als Erstlinientherapie zur Behandlung der chronischen Eisenüberladung auf Grund häufiger Transfusionen bei Patienten mit Beta-Thalassämia major.
- für die Behandlung von weiteren chronischen, transfusionsbedingten Eisenüberladungen, wenn eine Deferoxamin-Therapie kontraindiziert oder unangemessen ist.
- für die Behandlung der chronischen Eisenüberladung bei Patienten mit nicht transfusionsabhängigen Thalassämie-Syndromen im Alter von 10 Jahren und älter, wenn eine Deferoxamin-Therapie kontraindiziert oder unangemessen ist.
Therapien, die vor der Einführung der angepassten Limitierung (1. Juni 2023) begonnen wurden, werden weiterhin vergütet, sofern es sich um eine Behandlung entsprechend der von Swissmedic zugelassenen Indikation handelt.
More preparations in this group
FAQ
Is Deferasirox-Mepha covered by Swiss health insurance?
Yes, but only under conditions. Deferasirox-Mepha is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Deferasirox-Mepha cost in Switzerland?
The public price is the maximum price set by the FOPH and for Deferasirox-Mepha ranges from CHF 172.40 to CHF 1'086.05 per pack. The ex-factory price ranges from CHF 143.41 to CHF 983.53. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages